Skip to main content
. 2019 Apr 23;12:3077–3085. doi: 10.2147/OTT.S200754

Table 2.

Objective response in the 50 patients with locally advanced/metastatic pancreatic cancer, 18 patients receiving a full dose compared with the 32 patients receiving an attenuated dose

Objective response Patients n (%)(total=50) p-valuea
CR (All patients=50)
 Patients receiving an attenuated doses (n=32)
 Patients receiving a full doses (n=18)		 0 (0)
0 (0)
0 (0)		 1
PR (All patients=50)
 Patients receiving an attenuated doses (n=32)
 Patients receiving a full doses (n=18)		 15 (30)
11 (34.4)
4 (22.2)		 0.52
SD (All patients=50)
 Patients receiving an attenuated doses (n=32)
 Patients receiving a full doses (n=18)		 8 (16)
6 (18.8)
2 (11.1)		 0.69
PD (All patients=50)
 Patients receiving an attenuated doses (n=32)
 Patients receiving a full doses (n=18)		 20 (40)
13 (40.6)
7 (38.9)		 1

Note: ap-value calculated using Fisher’s exact test.

Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.